FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to obtaining peptides that bind to mutant protein p53; it can be used in medicine. Obtained peptides with SEQ ID NO: 426, 427, 429-431, 446, 448, 449, 452-455, 457-464 induce the expression by Mut-p53 protein of p53-selective inhibition of malignant tumor cells expressing mutant protein p53, and they can be used for the effective therapy of malignant tumors caused by mutant protein p53.
EFFECT: obtaining peptides for the therapy of malignant tumors caused by p53.
12 cl, 14 dwg, 3 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| PEPTIDE ANTAGONISTS OF CALCITONIN CGRP FAMILY OF PEPTIDE HORMONES AND THEIR USE | 2017 |
|
RU2742826C2 |
| PEPTIDES CAPABLE OF REACTIVATING P53 MUTANTS | 2014 |
|
RU2721423C2 |
| IMPROVED PEPTIDE DRUGS FOR TREATMENT OF NASH AND OTHER DISORDERS | 2019 |
|
RU2790209C2 |
| IL-17A-BINDING POLYPEPTIDES | 2016 |
|
RU2749712C2 |
| NEONATAL Fc RECEPTOR BINDING AFFIMERS | 2020 |
|
RU2817008C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING INSULIN AND GLUCAGON | 2019 |
|
RU2823246C2 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| COMBINATION THERAPY OF ANTIBODY TO PROGASTRIN AND IMMUNOTHERAPY FOR CANCER TREATMENT | 2018 |
|
RU2784604C2 |
| ANTIGENE PEPTIDES FOR CANCER PREVENTION AND TREATMENT | 2019 |
|
RU2812911C2 |
